Biogen
FDA greenlights Glenmark’s generic version of Biogen’s Tecfidera in relapsing multiple sclerosis
October 7, 2020Research and Development, Sales and Marketing Biogen, Glenmark, generic, multiple sclerosis
Glenmark Pharma will be celebrating after it secured FDA approval in the US to market dimethyl fumarate, a generic version …
Mylan secures first FDA approval for generic version of Biogen’s Tecfidera following patent dispute
August 20, 2020Sales and Marketing Biogen, FDA, Mylan, generic, tecfidera
The FDA has approved its first generic of Biogen’s multiple sclerosis (MS) treatment Tecfidera, awarding authorisation to Mylan which is …
Scottish Medicines Consortium approves new drugs in multiple sclerosis, ulcerative colitis and diabetes
April 15, 2020Research and Development, Sales and Marketing Biogen, Fambyra, Janssen, NHS, Rimzoic, Sandoz, Sanofi, Scotland, Scottish Medicines Consortium, Stelara, Suliqua, pharma
Medical regulation must still continue even in a global pandemic, and the Scottish Medicines Consortium, (SMC) has ploughed on with …
100 coronavirus cases linked to Biogen-hosted event in Boston, State of Massachusetts confirms
March 18, 2020Manufacturing and Production, Medical Communications, Research and Development Biogen, coronavirus, pharma
It is now known that around 100 of the known cases of the COVID-19 coronavirus can be traced to an …
Biogen and Takeda forced to send employees home as coronavirus hits Massachusetts
March 9, 2020Manufacturing and Production, Medical Communications Biogen, Takeda, coronavirus, pharma
Big pharma has been hit by the coronavirus (COVID-19) outbreak right on its doorstep, as two of the biggest names …
Biogen stock surges following patent victory over Mylan for Tecfidera
February 6, 2020Sales and Marketing Biogen, Mylan, multiple sclerosis, pharma, tecfidera
Biogen has emerged victorious in a patent dispute with Mylan relating to the latter’s multiple sclerosis therapy Tecfidera – a …
Biogen picks up Pfizer’s Phase 1 therapy for Alzheimer’s symptoms in potential $700m deal
January 14, 2020Manufacturing and Production, Sales and Marketing Alzheimer's, Biogen, Pfizer, pharma
Biogen has entered into an agreement with Pfizer to acquire the latter’s Phase 1 candidate PF-05251749 in order to develop …
Biogen terminates gosuranemab in progressive surpanuclear palsy following Phase 2 failure
December 16, 2019Research and Development, Sales and Marketing Biogen, pharma, trial failure
Biogen has revealed its intention to shut down further development of gosuranemab after results of a Phase 2 study showed …
Biogen scoops up eye and anti-TNF drug rights from Samsung Bioepis in $300m deal
November 7, 2019Sales and Marketing Biogen, Samsung Bioepis, pharma
Biogen has struck a new deal with Samsung Bioepis, it has emerged, picking up the commercialisation rights to a raft …
FDA approves Biogen and Alkermes’ Vumerity for relapsing multiple sclerosis
October 30, 2019Research and Development, Sales and Marketing Alkermes, Biogen, FDA, Vumerity, multiple sclerosis, pharma
The FDA has given the green light to Vumerity (diroximel fumarate), a novel oral fumarate developed by Biogen and Alkermes, …
Decade-long data support Biogen’s Tecfidera in relapsing multiple sclerosis
September 11, 2019Research and Development Biogen, multiple sclerosis, pharma, tecfidera
Biogen has revealed new long-term data for Tecfidera (dimethyl fumarate), reinforcing the benefits of the therapy over a decade-long period …
Four perspectives from life sciences companies on multichannel engagement
August 23, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bayer, Biogen, GSK, Lifesciences, Teva, healthcare, pharma
By 2020, 70% of HCPs are expected to be digital natives, whose experiences with mobile, social, and digital technologies in …
Biogen & Alkermes’ multiple sclerosis drug proves “statistically superior” to Tecfidera at Phase 3
July 31, 2019Research and Development Alkermes, Biogen, multiple sclerosis, pharma
Biogen and Alkermes have unveiled new Phase 3 data for diroximel fumarate, comparing the adequacy of the therapy to Biogen’s …
Biogen unveils promising new data for Spinraza in pre-symptomatic infants with spinal muscular atrophy
July 2, 2019Manufacturing and Production, Research and Development Biogen, Spinraza, pharma, spinal muscular atrophy
Biogen has introduced new data on the efficacy of Spinraza in the treatment of pre-symptomatic infants in spinal muscular atrophy …
Top Ten most popular articles on Pharmafile.com this week!
June 7, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Biogen, EMA, Janssen, Orkambi, Pfizer
It was revealed this week that Pfizer suppressed findings that their anti-inflammatory Enbrel reduced the risk of Alzheimer’s by 64%. …
Latest content
AstraZeneca’s Trixeo approved in EU for asthma
ESTEVE CDMO adds $17.5m to Illinois expansion
